The mPFS of the patients with dual drivers who received EGFR-TKI monotherapy was ∼8.0 months, which was shorter than the data in previous clinical trials for first-line EGFR-TKI therapy of patients with EGFR-mutant NSCLC.25, 26, 27 Similarly, the mPFS was 4 months for patients with dual drivers who received chemotherapy, which was also inferior to the data in previous studies.25, 26, 27 These data suggest that harboring concurrent EGFR mutation and MET overexpression/amplification at baseline has a negative impact on treatment outcome. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.